MEMO THERAPEUTICS

Memo Therapeutics AG ("MTx") is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx' lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. AntiBKV has successfully completed Phase I with no safety concerns, with Phase II (POC) data expected in H1 2025. MTx' pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus ("CMV"), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical.

Also known as: Memo Therapeutics AG

Primary location: Zurich Switzerland